@article{FrodlJanowitzSchmaaletal.2017, author = {Frodl, Thomas and Janowitz, Deborah and Schmaal, Lianne and Tozzi, Leonardo and Dobrowolny, Henrik and Stein, Dan J. and Veltman, Dick J. and Wittfeld, Katharina and van Erp, Theo G. M. and Jahanshad, Neda and Block, Andrea and Hegenscheid, Katrin and Voelzke, Henry and Lagopoulos, Jim and Hatton, Sean N. and Hickie, Ian B. and Frey, Eva Maria and Carballedo, Angela and Brooks, Samantha J. and Vuletic, Daniella and Uhlmann, Anne and Veer, Ilya M. and Walter, Henrik and Schnell, Knut and Grotegerd, Dominik and Arolt, Volker and Kugel, Harald and Schramm, Elisabeth and Konrad, Carsten and Zurowski, Bartosz and Baune, Bernhard T. and van der Wee, Nic J. A. and van Tol, Marie-Jose and Penninx, Brenda W. J. H. and Thompson, Paul M. and Hibar, Derrek P. and Dannlowski, Udo and Grabe, Hans J.}, title = {Childhood adversity impacts on brain subcortical structures relevant to depression}, series = {Journal of psychiatric research}, volume = {86}, journal = {Journal of psychiatric research}, publisher = {Elsevier}, address = {Oxford}, issn = {0022-3956}, doi = {10.1016/j.jpsychires.2016.11.010}, pages = {58 -- 65}, year = {2017}, abstract = {Childhood adversity plays an important role for development of major depressive disorder (MDD). There are differences in subcortical brain structures between patients with MDD and healthy controls, but the specific impact of childhood adversity on such structures in MDD remains unclear. Thus, aim of the present study was to investigate whether childhood adversity is associated with subcortical volumes and how it interacts with a diagnosis of MDD and sex. Within the ENIGMA-MDD network, nine university partner sites, which assessed childhood adversity and magnetic resonance imaging in patients with MDD and controls, took part in the current joint mega-analysis. In this largest effort world-wide to identify subcortical brain structure differences related to childhood adversity, 3036 participants were analyzed for subcortical brain volumes using FreeSurfer. A significant interaction was evident between childhood adversity, MDD diagnosis, sex, and region. Increased exposure to childhood adversity was associated with smaller caudate volumes in females independent of MDD. All subcategories of childhood adversity were negatively associated with caudate volumes in females - in particular emotional neglect and physical neglect (independently from age, ICV, imaging site and MDD diagnosis). There was no interaction effect between childhood adversity and MDD diagnosis on subcortical brain volumes. Childhood adversity is one of the contributors to brain structural abnormalities. It is associated with subcortical brain abnormalities that are relevant to psychiatric disorders such as depression. (C) 2016 Published by Elsevier Ltd.}, language = {en} } @article{WeckGrikscheitHoeflingetal.2016, author = {Weck, Florian and Grikscheit, Florian and H{\"o}fling, Volkmar and Kordt, Anne and Hamm, Alfons O. and Gerlach, Alexander L. and Alpers, Georg W. and Arolt, Volker and Kircher, Tilo and Pauli, Paul and Rief, Winfried and Lang, Thomas}, title = {The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia}, series = {Journal of anxiety disorders}, volume = {42}, journal = {Journal of anxiety disorders}, publisher = {Elsevier}, address = {Oxford}, issn = {0887-6185}, doi = {10.1016/j.janxdis.2016.05.007}, pages = {10 -- 18}, year = {2016}, abstract = {Treatment delivery factors (i.e., therapist adherence, therapist competence, and therapeutic alliance) are considered to be important for cognitive behavioral therapy (CBT) for panic disorder and agoraphobia (PD/AG). In the current study, four independent raters conducted process evaluations based on 168 two-hour videotapes of 84 patients with PD/AG treated with exposure-based CBT. Two raters evaluated patients' interpersonal behavior in Session 1. Two raters evaluated treatment delivery factors in Session 6, in which therapists provided the rationale for conducting exposure exercises. At the 6-month follow-up, therapists' adherence (r = 0.54) and therapeutic alliance (r = 0.31) were significant predictors of changes in agoraphobic avoidance behavior; therapist competence was not associated with treatment outcomes. Patients' interpersonal behavior in Session 1 was a significant predictor of the therapeutic alliance in Session 6 (r = 0.17). The findings demonstrate that treatment delivery factors, particularly therapist adherence, are relevant to the long-term success of CBT for PD/AG.}, language = {en} } @article{TschornRieckmannAroltetal.2019, author = {Tschorn, Mira and Rieckmann, Nina and Arolt, Volker and Beer, Katja and Haverkamp, Wilhelm and Martus, Peter and Waltenberger, Johannes and M{\"u}ller-Nordhorn, Jacqueline and Str{\"o}hle, Andreas}, title = {Erkennungsg{\"u}te dreier deutschsprachiger Screeninginstrumente f{\"u}r Depression bei hospitalisierten Patienten mit koronarer Herzerkrankung}, series = {Psychiatrische Praxis}, volume = {46}, journal = {Psychiatrische Praxis}, number = {1}, publisher = {Thieme}, address = {Stuttgart}, issn = {0303-4259}, doi = {10.1055/s-0042-123434}, pages = {41 -- 48}, year = {2019}, abstract = {Ziel Vergleich der Erkennungsg{\"u}te von drei Depressions-Screeninginstrumenten bei Patienten mit koronarer Herzerkrankung (KHK). Methodik 1019 KHK-Patienten erhielten den Patient Health Questionnaire (PHQ-9 und PHQ-2) und die Hospital Anxiety and Depression Scale (HADS-D) sowie ein klinisches Interview (Composite International Diagnostic Interview) als Referenzstandard. Ergebnisse Bez{\"u}glich der Erkennungsg{\"u}te waren PHQ-9 und HADS-D dem PHQ-2 {\"u}berlegen. Optimale Cut-off-Werte waren 7 (PHQ-9 und HADS-D) und 2 (PHQ-2). Schlussfolgerung PHQ-9 und HADS-D haben eine vergleichbare Diskriminationsf{\"a}higkeit f{\"u}r depressive St{\"o}rungen bei KHK-Patienten.}, language = {de} } @article{KuhlmannTschornAroltetal.2017, author = {Kuhlmann, Stella and Tschorn, Mira and Arolt, Volker and Beer, Katja and Brandt, Julia and Grosse, Laura and Haverkamp, Wilhelm and M{\"u}ller-Nordhorn, Jacqueline and Rieckmann, Nina and Waltenberger, Johannes and Warnke, Katharina and Hellweg, Rainer and Str{\"o}hle, Andreas}, title = {Serum brain-derived neurotrophic factor and stability of depressive symptoms in coronary heart disease patients}, series = {Psychoneuroendocrinology : an international journal ; the official journal of the International Society of Psychoneuroendocrinology}, volume = {77}, journal = {Psychoneuroendocrinology : an international journal ; the official journal of the International Society of Psychoneuroendocrinology}, publisher = {Elsevier Science}, address = {Oxford}, issn = {0306-4530}, doi = {10.1016/j.psyneuen.2016.12.015}, pages = {196 -- 202}, year = {2017}, abstract = {Objective: Brain-derived neurotrophic factor (BDNF) supports neurogenesis, angiogenesis, and promotes the survival of various cell types in the brain and the coronary system. Moreover, BDNF is associated with both coronary heart disease (CHD) and depression. The current study aims to investigate whether serum BDNF levels are associated with the course of depressive symptoms in CHD patients. Methods: At baseline, N = 225 CHD patients were enrolled while hospitalized. Of these, N = 190 (84\%) could be followed up 6 months later. Depressive symptoms were assessed both at baseline and at the 6-months follow-up using the Patient Health Questionnaire (PHQ-9). Serum BDNF concentrations were measured using fluorometric Enzyme-linked immunosorbent assays (ELISA). Results: Logistic regression models showed that lower BDNF levels were associated with persistent depressive symptoms, even after adjustment for age, sex, smoking and potential medical confounders. The incidence of depressive symptoms was not related to lower BDNF levels. However, somatic comorbidity (as measured by the Charlson Comorbidity Index) was significantly associated with the incidence of depressive symptoms. Conclusions: Our findings suggest a role of BDNF in the link between CHD and depressive symptoms. Particularly, low serum BDNF levels could be considered as a valuable biomarker for the persistence of depressive symptoms among depressed CHD patients.}, language = {en} } @misc{TschornKuhlmannRieckmannetal.2020, author = {Tschorn, Mira and Kuhlmann, Stella Linnea and Rieckmann, Nina and Beer, Katja and Grosse, Laura and Arolt, Volker and Waltenberger, Johannes and Haverkamp, Wilhelm and M{\"u}ller-Nordhorn, Jacqueline and Hellweg, Rainer and Str{\"o}hle, Andreas}, title = {Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease}, series = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe}, journal = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe}, number = {1}, issn = {1866-8364}, doi = {10.25932/publishup-55731}, url = {http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-557315}, pages = {11}, year = {2020}, abstract = {Objective: Depression and coronary heart disease (CHD) are highly comorbid conditions. Brain-derived neurotrophic factor (BDNF) plays an important role in cardiovascular processes. Depressed patients typically show decreased BDNF concentrations. We analysed the relationship between BDNF and depression in a sample of patients with CHD and additionally distinguished between cognitive-affective and somatic depression symptoms. We also investigated whether BDNF was associated with somatic comorbidity burden, acute coronary syndrome (ACS) or congestive heart failure (CHF). Methods: The following variables were assessed for 225 hospitalised patients with CHD: BDNF concentrations, depression [Patient Health Questionnaire-9 (PHQ-9)], somatic comorbidity (Charlson Comorbidity Index), CHF, ACS, platelet count, smoking status and antidepressant treatment. Results: Regression models revealed that BDNF was not associated with severity of depression. Although depressed patients (PHQ-9 score >7) had significantly lower BDNF concentrations compared to non-depressed patients (p = 0.04), this was not statistically significant after controlling for confounders (p = 0.15). Cognitive-affective symptoms and somatic comorbidity burden each closely missed a statistically significant association with BDNF concentrations (p = 0.08, p = 0.06, respectively). BDNF was reduced in patients with CHF (p = 0.02). There was no covariate-adjusted, significant association between BDNF and ACS. Conclusion: Serum BDNF concentrations are associated with cardiovascular dysfunction. Somatic comorbidities should be considered when investigating the relationship between depression and BDNF.}, language = {en} } @article{TschornKuhlmannRieckmannetal.2020, author = {Tschorn, Mira and Kuhlmann, Stella Linnea and Rieckmann, Nina and Beer, Katja and Grosse, Laura and Arolt, Volker and Waltenberger, Johannes and Haverkamp, Wilhelm and M{\"u}ller-Nordhorn, Jacqueline and Hellweg, Rainer and Str{\"o}hle, Andreas}, title = {Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease}, series = {Acta Neuropsychiatrica}, volume = {33}, journal = {Acta Neuropsychiatrica}, number = {1}, publisher = {Cambridge Univ. Press}, address = {Cambridge}, issn = {1601-5215}, doi = {10.1017/neu.2020.31}, pages = {22 -- 30}, year = {2020}, abstract = {Objective: Depression and coronary heart disease (CHD) are highly comorbid conditions. Brain-derived neurotrophic factor (BDNF) plays an important role in cardiovascular processes. Depressed patients typically show decreased BDNF concentrations. We analysed the relationship between BDNF and depression in a sample of patients with CHD and additionally distinguished between cognitive-affective and somatic depression symptoms. We also investigated whether BDNF was associated with somatic comorbidity burden, acute coronary syndrome (ACS) or congestive heart failure (CHF). Methods: The following variables were assessed for 225 hospitalised patients with CHD: BDNF concentrations, depression [Patient Health Questionnaire-9 (PHQ-9)], somatic comorbidity (Charlson Comorbidity Index), CHF, ACS, platelet count, smoking status and antidepressant treatment. Results: Regression models revealed that BDNF was not associated with severity of depression. Although depressed patients (PHQ-9 score >7) had significantly lower BDNF concentrations compared to non-depressed patients (p = 0.04), this was not statistically significant after controlling for confounders (p = 0.15). Cognitive-affective symptoms and somatic comorbidity burden each closely missed a statistically significant association with BDNF concentrations (p = 0.08, p = 0.06, respectively). BDNF was reduced in patients with CHF (p = 0.02). There was no covariate-adjusted, significant association between BDNF and ACS. Conclusion: Serum BDNF concentrations are associated with cardiovascular dysfunction. Somatic comorbidities should be considered when investigating the relationship between depression and BDNF.}, language = {en} } @misc{KuhlmannTschornAroltetal.2017, author = {Kuhlmann, Stella L. and Tschorn, Mira and Arolt, Volker and Beer, Katja and Brandt, Julia and Grosse, Laura and Haverkamp, Wilhelm and Mueller-Nordhorn, Jacqueline and Rieckmann, Nina and Waltenberger, Johannes and Warnke, Katharina and Hellweg, Rainer and Stroehle, Andreas}, title = {Serum brain-derived neurotrophic factor and depressive symptoms in coronary heart disease patients: Role of cognitive functions Reply}, series = {Psychoneuroendocrinology}, volume = {79}, journal = {Psychoneuroendocrinology}, publisher = {Elsevier}, address = {Oxford}, issn = {0306-4530}, doi = {10.1016/j.psyneuen.2017.02.010}, pages = {175 -- 176}, year = {2017}, language = {en} }